(Q34294365)

English

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

1 reference

23 September 2020

Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature (English)

1 reference

Europe PubMed Central

1 August 2017

colorectal neoplasm

1 reference

23 September 2020

randomized controlled trial

1 reference

19 September 2019

humanized antibody

1 reference

27 September 2019

1 reference

based on heuristic

inferred from title

antineoplastic combined chemotherapy protocols

1 reference

23 September 2020

colorectal carcinoma

1 reference

based on heuristic

inferred from title

object named as

Dirk Arnold

4

1 reference

ORCID Public Data File 2021

author name string

Alexander Stein

1

1 reference

Europe PubMed Central

1 August 2017

Gabriel Glockzin

2

1 reference

Europe PubMed Central

1 August 2017

Andreas Wienke

3

1 reference

Europe PubMed Central

1 August 2017

Thomas Edelmann

5

1 reference

Europe PubMed Central

1 August 2017

Bert Hildebrandt

6

1 reference

Europe PubMed Central

1 August 2017

Stephan Hollerbach

7

1 reference

Europe PubMed Central

1 August 2017

Gerald Illerhaus

8

1 reference

Europe PubMed Central

1 August 2017

Alfred Königsrainer

9

1 reference

Europe PubMed Central

1 August 2017

Michael Richter

10

1 reference

Europe PubMed Central

1 August 2017

Hans J Schlitt

11

1 reference

Europe PubMed Central

1 August 2017

Hans-Joachim Schmoll

12

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

16 August 2012

9 references

Europe PubMed Central

1 August 2017

21 March 2019

3 April 2019

25 June 2019

19 September 2019

27 September 2019

27 November 2019

13 December 2019

23 September 2020

9 references

Europe PubMed Central

1 August 2017

21 March 2019

3 April 2019

25 June 2019

19 September 2019

27 September 2019

27 November 2019

13 December 2019

23 September 2020

12

1 reference

Europe PubMed Central

1 August 2017

356

1 reference

Europe PubMed Central

1 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

8 references

Europe PubMed Central

21 March 2019

Europe PubMed Central

3 April 2019

Europe PubMed Central

25 June 2019

Europe PubMed Central

19 September 2019

Europe PubMed Central

27 September 2019

Europe PubMed Central

27 November 2019

Europe PubMed Central

13 December 2019

Europe PubMed Central

23 September 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

https://scigraph.springernature.com/pub.10.1186/1471-2407-12-356

0 references

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Actual 10-year survival after resection of colorectal liver metastases defines cure.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Proposal of a new and simple staging system of colorectal liver metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Towards a pan-European consensus on the treatment of patients with colorectal liver metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Survival after hepatic resection for colorectal metastases: a 10-year experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

6 July 2018

Surgical management and outcomes of colorectal cancer liver metastases

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-356

21 January 2018

Extended resections of liver metastases from colorectal cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-356

21 January 2018

Urgent need for a new staging system in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-356

21 January 2018

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-356

21 January 2018

A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-356

21 January 2018

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-356

21 January 2018

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-356

21 January 2018

Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-356

21 January 2018

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-356

21 January 2018

Optimising the design of phase II oncology trials: the importance of randomisation.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-356

21 January 2018

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-356

21 January 2018

Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

28 October 2018

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

28 October 2018

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

28 October 2018

Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3503684

28 October 2018

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-356

21 January 2018

Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22897915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of synchronous liver metastases in patients with colorectal cancer in relationship to clinico-pathologic characteristics. Results of a German prospective multicentre observational study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22897915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new classification system for liver metastases from colorectal cancer in Japanese multicenter analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22897915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22897915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22897915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22897915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resection of colorectal liver metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/22897915

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-12-356

1 reference

Europe PubMed Central

1 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34294365&oldid=1952300974"